Tolvaptan and Furosemide Combination Therapy

Patient Monitoring and Safety

• The American Association for the Study of Liver Diseases recommends serum sodium monitoring to avoid overly rapid correction, with treatment started in the hospital and sodium checks to ensure increases do not exceed 8-10 mmol/L per day 1
• The European Association for the Study of the Liver suggests volume status requires careful assessment, monitoring for signs of dehydration, thirst, and hypotension 2
• The National Kidney Foundation advises electrolytes (potassium, sodium) and renal function need regular monitoring 3

Contraindications and Precautions

• The American College of Gastroenterology recommends avoiding tolvaptan in patients with altered mental state who cannot drink adequate fluids, due to risk of severe dehydration and hypernatremia 1
• The European Society of Cardiology suggests avoiding combination therapy in marked hypovolemia or hypotension (SBP <90-100 mmHg), as both drugs can worsen hypoperfusion in this setting 1, 3

Practical Dosing Approach

• The Heart Failure Society of America recommends continuing baseline furosemide dose and adding tolvaptan 15 mg orally once daily, titrating to 30-60 mg based on response and sodium levels 1, 3
• The American Association for the Study of Liver Diseases suggests using tolvaptan only for severe hyponatremia (<125 mmol/L) refractory to fluid restriction, starting with low doses (7.5-15 mg) given hepatotoxicity concerns 1, 2